Cargando…

The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression

BACKGROUND: Prostate cancer (CaP) is a disease with multifactorial etiology that includes both genetic and environmental components. The knowledge of the genetic basis of CaP has increased over the past years, mainly in the pathways that underlie tumourigenesis, progression and drug resistance. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Simon, Yoshimoto, Maisa, Beheshti, Ben, Houlston, Richard S, Squire, Jeremy A, Evans, Andrew
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1450280/
https://www.ncbi.nlm.nih.gov/pubmed/16573809
http://dx.doi.org/10.1186/1471-2164-7-65
_version_ 1782127387111063552
author Hughes, Simon
Yoshimoto, Maisa
Beheshti, Ben
Houlston, Richard S
Squire, Jeremy A
Evans, Andrew
author_facet Hughes, Simon
Yoshimoto, Maisa
Beheshti, Ben
Houlston, Richard S
Squire, Jeremy A
Evans, Andrew
author_sort Hughes, Simon
collection PubMed
description BACKGROUND: Prostate cancer (CaP) is a disease with multifactorial etiology that includes both genetic and environmental components. The knowledge of the genetic basis of CaP has increased over the past years, mainly in the pathways that underlie tumourigenesis, progression and drug resistance. The vast majority of cases of CaP are adenocarcinomas that likely develop through a pre-malignant lesion and high-grade prostatic intraepithelial neoplasia (HPIN). Histologically, CaP is a heterogeneous disease consisting of multiple, discrete foci of invasive carcinoma and HPIN that are commonly interspersed with benign glands and stroma. This admixture with benign tissue can complicate genomic analyses in CaP. Specifically, when DNA is bulk-extracted the genetic information obtained represents an average for all of the cells within the sample. RESULTS: To minimize this problem, we obtained DNA from individual foci of HPIN and CaP by laser capture microdissection (LCM). The small quantities of DNA thus obtained were then amplified by means of multiple-displacement amplification (MDA), for use in genomic DNA array comparative genomic hybridisation (gaCGH). Recurrent chromosome copy number abnormalities (CNAs) were observed in both HPIN and CaP. In HPIN, chromosomal imbalances involving chromosome 8 where common, whilst in CaP additional chromosomal changes involving chromosomes 6, 10, 13 and 16 where also frequently observed. CONCLUSION: An overall increase in chromosomal changes was seen in CaP compared to HPIN, suggesting a universal breakdown in chromosomal stability. The accumulation of CNAs, which occurs during this process is non-random and may indicate chromosomal regions important in tumourigenesis. It is therefore likely that the alterations in copy number are part of a programmed cycle of events that promote tumour development, progression and survival. The combination of LCM, MDA and gaCGH is ideally suited for the identification of CNAs from small cell clusters and may assist in the discovery of potential genomic markers for early diagnosis, or identify the location of tumour suppressor genes (TSG) or oncogenes previously unreported in HPIN and CaP.
format Text
id pubmed-1450280
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14502802006-04-29 The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression Hughes, Simon Yoshimoto, Maisa Beheshti, Ben Houlston, Richard S Squire, Jeremy A Evans, Andrew BMC Genomics Research Article BACKGROUND: Prostate cancer (CaP) is a disease with multifactorial etiology that includes both genetic and environmental components. The knowledge of the genetic basis of CaP has increased over the past years, mainly in the pathways that underlie tumourigenesis, progression and drug resistance. The vast majority of cases of CaP are adenocarcinomas that likely develop through a pre-malignant lesion and high-grade prostatic intraepithelial neoplasia (HPIN). Histologically, CaP is a heterogeneous disease consisting of multiple, discrete foci of invasive carcinoma and HPIN that are commonly interspersed with benign glands and stroma. This admixture with benign tissue can complicate genomic analyses in CaP. Specifically, when DNA is bulk-extracted the genetic information obtained represents an average for all of the cells within the sample. RESULTS: To minimize this problem, we obtained DNA from individual foci of HPIN and CaP by laser capture microdissection (LCM). The small quantities of DNA thus obtained were then amplified by means of multiple-displacement amplification (MDA), for use in genomic DNA array comparative genomic hybridisation (gaCGH). Recurrent chromosome copy number abnormalities (CNAs) were observed in both HPIN and CaP. In HPIN, chromosomal imbalances involving chromosome 8 where common, whilst in CaP additional chromosomal changes involving chromosomes 6, 10, 13 and 16 where also frequently observed. CONCLUSION: An overall increase in chromosomal changes was seen in CaP compared to HPIN, suggesting a universal breakdown in chromosomal stability. The accumulation of CNAs, which occurs during this process is non-random and may indicate chromosomal regions important in tumourigenesis. It is therefore likely that the alterations in copy number are part of a programmed cycle of events that promote tumour development, progression and survival. The combination of LCM, MDA and gaCGH is ideally suited for the identification of CNAs from small cell clusters and may assist in the discovery of potential genomic markers for early diagnosis, or identify the location of tumour suppressor genes (TSG) or oncogenes previously unreported in HPIN and CaP. BioMed Central 2006-03-30 /pmc/articles/PMC1450280/ /pubmed/16573809 http://dx.doi.org/10.1186/1471-2164-7-65 Text en Copyright © 2006 Hughes et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Hughes, Simon
Yoshimoto, Maisa
Beheshti, Ben
Houlston, Richard S
Squire, Jeremy A
Evans, Andrew
The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
title The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
title_full The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
title_fullStr The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
title_full_unstemmed The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
title_short The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
title_sort use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1450280/
https://www.ncbi.nlm.nih.gov/pubmed/16573809
http://dx.doi.org/10.1186/1471-2164-7-65
work_keys_str_mv AT hughessimon theuseofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT yoshimotomaisa theuseofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT beheshtiben theuseofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT houlstonrichards theuseofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT squirejeremya theuseofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT evansandrew theuseofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT hughessimon useofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT yoshimotomaisa useofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT beheshtiben useofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT houlstonrichards useofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT squirejeremya useofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression
AT evansandrew useofwholegenomeamplificationtostudychromosomalchangesinprostatecancerinsightsintogenomewidesignatureofpreneoplasiaassociatedwithcancerprogression